NCT02457559View on ClinicalTrials.gov

Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 10, 2015

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Relapsed/Refractory B-cell Malignancies
Interventions
DRUG

Tirabrutinib

Tablets or capsules administered orally

Trial Locations (6)

34295

Hopital Saint Eloi, Montpellier

59037

CHRU de Lille, Lille

69310

Centre Hospitalier Lyon Sud, Pierre-Bénite

CF14 4XW

University Hospital of Wales, Cardiff

LE1 5WW

Leicester Royal Infirmary, Leicester

PL68DH

Derriford Hospital, Plymouth

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY